{
    "clinical_study": {
        "@rank": "77242", 
        "arm_group": {
            "arm_group_label": "Single Arm", 
            "arm_group_type": "Experimental", 
            "description": "ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 weeks"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 and\n      ABT-333 coadministered with RBV in HCV genotype 1 adults taking Methadone or Buprenorphine."
        }, 
        "brief_title": "An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatitis C", 
            "HCV", 
            "Chronic Hepatitis C"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic HCV-infection prior to study enrollment.\n\n          -  Screening laboratory result indicating HCV genotype 1-infection.\n\n          -  Subject must be treatment naive or previous pegylated interferon/ribavirin treatment\n             experienced.\n\n          -  Subjects must be on a stable opioid replacement therapy of methadone or buprenorphine\n             \u00b1 naloxone for at least 6 months prior to screening.\n\n        Exclusion Criteria:\n\n          -  Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human\n             Immunodeficiency virus antibody (HIV Ab) at screening.\n\n          -  Prior therapy with direct acting antiviral agents for the treatment of HCV, including\n             telaprevir and boceprevir.\n\n          -  Females who are pregnant or plan to become pregnant, or breastfeeding, or males whose\n             partners are pregnant or planning to become pregnant within 7 months (or per local\n             RBV label) after their last dose of study drug.\n\n          -  Any current or past clinical evidence of cirrhosis such as ascites or esophageal\n             varices, or prior biopsy showing cirrhosis, e.g., a Metavir Score of >3 or Ishak\n             score of > 4."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911845", 
            "org_study_id": "M14-103"
        }, 
        "intervention": [
            {
                "arm_group_label": "Single Arm", 
                "description": "tablet", 
                "intervention_name": "ABT-450/r/ABT-267", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Single Arm", 
                "description": "tablet", 
                "intervention_name": "ABT-333", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Single Arm", 
                "description": "tablet", 
                "intervention_name": "Ribovirin (RBV)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Methadone", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "HCV Genotype 1", 
            "Hepatitis Genotype 1", 
            "Interferon Free", 
            "methadone", 
            "HCV", 
            "Buprenorphine", 
            "Hepatitis C"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35215"
                    }, 
                    "name": "Site Reference ID/Investigator# 100498"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bakersfield", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93301"
                    }, 
                    "name": "Site Reference ID/Investigator# 100755"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Site Reference ID/Investigator# 100522"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shreveport", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "71103"
                    }, 
                    "name": "Site Reference ID/Investigator# 100495"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poughkeepsie", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "12601"
                    }, 
                    "name": "Site Reference ID/Investigator# 100756"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Site Reference ID/Investigator# 100521"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Annandale", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22003"
                    }, 
                    "name": "Site Reference ID/Investigator# 100497"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }, 
                    "name": "Site Reference ID/Investigator# 100496"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Single-Arm, Phase 2 Study to Evaluate the Combination of ABT-450/r/ABT-267 and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Hepatitis C Virus (HCV) Infection Taking Methadone or Buprenorphine", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Dan  Cohen, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Hepatitis C virus ribonucleic acid less than the lower limit of quantification", 
            "measure": "Percentage of subjects with sustained virologic response 12 weeks post-treatment", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911845"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hepatitis C virus ribonucleic acid greater than the lower limit of quantification", 
                "measure": "The percentage of subjects with virologic failure during treatment", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "Hepatitis C virus ribonucleic acid greater than the lower limit of quantification", 
                "measure": "The percentage of subjects with relapse post treatment", 
                "safety_issue": "No", 
                "time_frame": "48 weeks after all subjects complete 12 week treatment period"
            }, 
            {
                "description": "To determine AUC, Cmax, Tmax and C trough for at least 20 subjects participating in intensive PK sampling", 
                "measure": "Pharmacokinetics (PK)", 
                "safety_issue": "No", 
                "time_frame": "One visit per subject between treatment week 2 and treatment week 12"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}